Business Model Breakdown
How CareDx Inc Makes Money
CDNA
Market Cap
$938M
Annual Revenue
$380M
Profit Margin
17.1%
Employees
644
The Short Version
CareDx Inc operates in the highly specialized field of transplant diagnostics. The company develops and commercializes non-invasive diagnostic tests that help monitor the health of transplanted organs, such as kidneys, hearts, and lungs. By providing critical genetic and molecular information, these tests assist clinicians in detecting potential organ rejection early, allowing for timely intervention and improving patient outcomes. Their business model primarily revolves around providing these recurring testing services to transplant centers, hospitals, and physicians globally.
Where the Revenue Comes From
Diagnostic testing services for transplant surveillance (~90% estimated)
Digital solutions and related services (~10% estimated)
Who buys: Transplant centers, hospitals, and physicians who manage solid organ transplant patients.
Why It Works (Competitive Advantages)
- ✔Intangible Assets/IP (Patents and proprietary technology in transplant diagnostics)
- ✔Switching Costs (Physician reliance on specific diagnostic tests and protocols)
Economic Moat: Narrow (Intangible Assets/IP (Proprietary diagnostic tests, patents, clinical data), Switching Costs (Established relationships with transplant centers, integration into clinical workflows))
What Our Analysis Says
DVR Score as of April 6, 2026
CareDx Inc continues to face significant challenges that make a 10x growth within 3-5 years highly improbable. The Q4 2025 EPS miss and negative TTM EBITDA highlight ongoing profitability struggles, reinforcing the previous assessment of a challenged financial trajectory and unsustainable path. While the company maintains a strong balance sheet with a 2.86x current ratio and low debt-to-equity of 0.09x, this strength is offset by the lack of positive free cash flow and persistent unprofitability. The absence of updates on competitive moat erosion and ongoing legal battles from the previous analysis means these concerns likely persist. There are no clear, identifiable catalysts for exponential growth, with forecasted Q1 2026 revenue representing only modest growth. Insider activity is routine, and overall sentiment indicators are scarce. The stock remains a high-risk turnaround play focused on stabilization rather than hyper-growth.